Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis.

van Marcke C, Pogoda K, Fenton H, Vallet M, Plavc G, Borges M, Yousuf H, Dumas E, Berliere M, Ciliberto G, Duhoux FP, Fano V, Hall P, Kolenc Mokotar K, Lopes Conceicao L, Pereira F, Škoporc A, Thomas A, Tramonti G, van Bockstal MR, Vici P, Uher M, Krasniqi E

Open source

DOI: 10.1016/j.esmorw.2025.100158
Published: 2025 Sep
Container: ESMO real world data and digital oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmorw.2025.100158,
  title = {Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis.},
  author = {van Marcke C and Pogoda K and Fenton H and Vallet M and Plavc G and Borges M and Yousuf H and Dumas E and Berliere M and Ciliberto G and Duhoux FP and Fano V and Hall P and Kolenc Mokotar K and Lopes Conceicao L and Pereira F and Škoporc A and Thomas A and Tramonti G and van Bockstal MR and Vici P and Uher M and Krasniqi E},
  year = {2025},
  journal = {ESMO real world data and digital oncology},
  doi = {10.1016/j.esmorw.2025.100158},
  url = {https://doi.org/10.1016/j.esmorw.2025.100158}
}

RIS

TY  - JOUR
TI  - Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis.
AU  - van Marcke C
AU  - Pogoda K
AU  - Fenton H
AU  - Vallet M
AU  - Plavc G
AU  - Borges M
AU  - Yousuf H
AU  - Dumas E
AU  - Berliere M
AU  - Ciliberto G
AU  - Duhoux FP
AU  - Fano V
AU  - Hall P
AU  - Kolenc Mokotar K
AU  - Lopes Conceicao L
AU  - Pereira F
AU  - Škoporc A
AU  - Thomas A
AU  - Tramonti G
AU  - van Bockstal MR
AU  - Vici P
AU  - Uher M
AU  - Krasniqi E
PY  - 2025
JO  - ESMO real world data and digital oncology
DO  - 10.1016/j.esmorw.2025.100158
UR  - https://doi.org/10.1016/j.esmorw.2025.100158
ER  -

APA

C, V. M., K, P., H, F., M, V., G, P., M, B., H, Y., E, D., M, B., G, C., FP, D., V, F., P, H., K, K. M., L, L. C., F, P., A, Š., A, T., G, T., MR, V. B., P, V., M, U., & E, K. (2025). Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis.. ESMO real world data and digital oncology. https://doi.org/10.1016/j.esmorw.2025.100158

Source records

pubmed · retrieved 2026-09-26T19:43:45.436Z